XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 21, 2023
Jun. 26, 2022
Jul. 31, 2021
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Description for advisory agreement     the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023      
Stocked based compensation       $ 340,194 $ 0  
Payment of additional tax       99,644    
General and administrative expenses       $ 231,750 $ 0  
Four Third Party Consultants [Member]            
Awarded shares 970,000          
Awarded share value $ 999,100          
Phase 1 [Member]            
Project cost   $ 838,450        
Phase 2 [Member]            
Project cost   $ 907,084        
National Medicines Agency [Member] | General and administrative expenses [Member]            
Imposed fine           $ 16,214
Stocked based compensation           $ 77,250